



IESRT

2<sup>nd</sup>

MASTER CLASSES

Nancy 2010

# INTERNATIONAL EXPERTISE OF SPECIFIC RHINOLOGIC TOPICS

## FINAL PROGRAMME

December

10

11

12

2010

Under the aegis of  
Société Française d'ORL - Collège Français d'ORL  
Association Française de Rhinologie - European Rhinologic Society

The 1<sup>st</sup> IESRT meeting, held in Nancy in December 2008, has been a rich experience in exchanging new ideas and concepts ([www.iesrt.com](http://www.iesrt.com)).

Therefore we want to repeat this experience in December 10<sup>th</sup>-12<sup>th</sup>, 2010 with the same objectives: trying to understand nose and sinus diseases beyond the current consensus and progress in diagnosis and treatment.

Allergic reactions and the ostio-meatal complex are not sufficient to understand the wide range of dysfunctions in the nose & sinus organ. The rhinosinusitis concept, which sees nose and sinus as a single entity, is inadequate to understand why different pathologies do preferentially develop in specific anatomic area of the nose or sinuses.

Another way to understand physiology and pathology, diagnosis and treatment of the olfactory and respiratory noses and of the sinuses can be drawn from our knowledge in 1) the embryonic development of the olfactory placode, nasal cavities and sinuses and 2) the phylogenetic evolution showing how the olfactory organ has been caught by our respiratory apparatus. Besides its roles in respiration and olfaction, the nose has an aesthetic role. Nasal pyramid's morphology is in part determined by the antagonistic growing of its cartilaginous and bony components, especially at the level of the nasal septum. If one considers the septolateral unit as a keystone placed between the maxillo-nasal arches of the bony nasal pyramid and the alar cartilages of the nasal tip, then septorhinoplasty can be decomposed in three fundamental steps in order to restore the natural aesthetic and the breathing function of the nose.

The nose (the current septo-pyramido-naso-sinusal organ) is originally a sensory (olfactory) organ, to which Evolution has added respiratory and aesthetic roles. The 2010 IESRT meeting is aimed to look at new and practical insights into these three faces of Rhinology.

Welcome to Nancy for these exceptional master classes and to present your ideas and work to the experts.


R. Jankowski

**Friday, December 10 - 2010**

- 10:15 – 10:30** *Introduction to the meeting*  
Is there a different way to understand the nose?  
*R. Jankowski (France)*

## **FROM PHYLOGENY AND ONTOGENY TO HUMAN NOSE ANATOMY, PHYSIOLOGY AND DISEASES**

**10:30 – 12:15** **PHYLOGENY AND ONTOGENY OF THE PRIMARY NOSE**  
Moderators: *P. HELLINGS (Belgium), H. STAMMBERGER (Austria)*

- 10:30** **Exaptation = a mechanism of evolution of species.**  
*P. Picq (France)*
- 10:50** **Origin and phylogenic evolution of the air-breathing organ in Vertebrates**  
*E. Roux (France)*
- 11:10** **Phylogenic development of the primary nose and palate: from aquatic to aerial life**  
*R. Jankowski (France)*
- 11:25** **Human embryonic development of the primary nose and palate**  
*C. Nemos, B. Foliguet (France)*
- 11:40** **Does ontogenic development summarize phylogenic evolution? Critical analysis of Haeckel's theory.**  
*P. Picq (France)*
- 12:00** **Questions from the audience**
- 12:15 - 14:00** **Partner's exhibition**
- 12:30 - 13:30** **Symposium Morita**   
Lunch box will be provided by Morita in the exhibition area at the end of the symposium

**14:00 – 16:00** **OLFACTORY NOSE, RESPIRATORY NOSE AND PARANASAL SINUSES**  
Moderators: *P. PICQ (France), E. SERRANO (France)*

- 14:00** **Holoprosencephaly: a spectrum of abnormal developments of the face and midfacial skeleton associated to the absence of olfactory tracts**  
*I. Kjaer (Denmark)*
- 14:30** **Lessons from holoprosencephalic foetopsies: no olfactory system means no olfactory and no respiratory noses**  
*C. Nemos, B. Foliguet, L. Mainard, R. Jankowski (France)*

**Friday, December 10 - 2010**

- 14:50** From holoprosencephaly to the phylogenic and embryonic development of the nose: primary versus secondary palate, olfactory versus respiratory nose  
*R. Jankowski, L. Mainard, B. Foliguet (France)*
- 15:10** The human ethmoid bone: phylogenic origin, ontogenic development, nature and biology  
*S. Marquez (USA)*
- 15:40** The phylogenetic history of paranasal air sinuses: intracapsular versus extracapsular recesses.  
*S. Marquez (USA)*

**16:00 – 16:30** Coffee break – Partners' exhibition

**16:30 – 17:30** TWO CONCEPTS OF NOSE AND SINUS DISEASES

Moderators: *A. COSTE (France), JS. LACROIX (France)*

- 16:30** The rhinosinusitis theory to approach nose and sinus diseases  
*P. Hellings (Belgium)*
- 17:00** The phylo-ontogenic theory to approach nose and sinus diseases  
*R. Jankowski (France)*

**17:30 – 18:30** ROUND TABLE: INTER-DISCIPLINES DISCUSSION

*Should the nose be considered as one rhinosinusal organ or a combination of three organs (olfactory nose, respiratory nose, paranasal sinuses)?*

Moderators: *P. HELLINGS (Belgium), R. JANKOWSKI (France)*

Pannel: *A. Coste - Rhinologist (France)*  
*B. Foliguet - Embryologist (France)*  
*E. Roux - Pneumologist (France)*  
*E. Serrano - Rhinologist (France)*  
*H. Stammberger - Rhinologist (Austria)*  
*I. Kjaer - Embryologist (Denmark)*  
*JS. Lacroix - Rhinologist (Switzerland)*  
*P. Picq - Anthropologist (France)*  
*S. Marquez - Anthropologist (USA)*

**Saturday, December 11 - 2010**

## **SURGERY OF THE ETHMOID LABYRINTH**

**08:00 – 09:00 PATHOPHYSIOLOGICAL CONCEPTS LEADING ETHMOID SURGERY**

Moderators: *P. ELOY (Belgium), E. SERRANO (France)*

- 08:00 Is the ethmoid labyrinth a sinus?**  
*R. Jankowski (France)*
- 08:15 Do biofilms, fungal allergy and staph superantigens concepts impact on surgery?**  
*JS. Lacroix (Switzerland)*
- 08:30 The ostiomeatal complex: anatomy, pathophysiology and surgery**  
*H. Stammberger (Austria)*
- 08:45 Nasal polyposis: a model of ethmoidal disease**  
*R. Jankowski (France)*

**09:00 – 10:00 ROUND TABLE: HOW DO I OPERATE ON NASAL POLYPOSIS?**

Moderators: *E. SERRANO (France), P. ELOY (Belgium)*

Answers: *A. Coste (France)*

*H. Stammberger (Austria)*

*R. Jankowski (France)*

*Question from the audience*

**10:00 – 10:30 Coffee break– Partners' exhibition**

## **DISEASES OF THE OLFACTORY CLEFT**

**10:30-12:45 POLYPS AND TUMOURS OF THE OLFACTORY CLEFT**

Moderators: *H. STAMMBERGER (Austria), P. ROMBAUX (Belgium)*

- 10:30 Radio-anatomy and pathology of olfactory cleft tumours**  
*P. Henrot, P. Gallet (France)*
- 11:00 Respiratory epithelial adenomatoid hamartomas of the olfactory clefts (REAHOC)**  
*R. Jankowski (France)*

**Saturday, December 11 - 2010**

- 11:30 Endoscopic resection of olfactory esthesioneuromas**  
*H. Stammberger (Austria)*
- 12:00 Endoscopic exenteration of the olfactory cleft in woodworker's adenocarcinomas**  
*R. Jankowski (France)*
- 12:30 Rares tumours of the olfactory cleft**  
*D. Stoll (France)*

**12:45 – 14:15 Partners' exhibition**

**13:00 – 14:00 Symposium Ethicon: Surgiflo\*, place of this haemostatic agent in sinus surgery**

*Moderator: A. COSTE (France)*

**My experience with Surgiflo\* in Rhinology**

*R. Jankowski (France)*

**Multicenter study**

*L. Tavernier (France)*

**Pharmaco-economic modelisation**

*P. Bastide (France)*

*Lunch box will be provided by Ethicon in the exhibition area at the end of the symposium*

**ETHICON**  
a Johnson & Johnson company

**14:15 - 15:15 OLFACTORY CLEFT, MENINGOENCEPHALOCELE AND CSF LEAK**  
*Moderators: P. ELOY (Belgium), D. STOLL (France)*

- 14:15 Localisation diagnosis of a CSF rhinorrhea**  
*P. Eloy (Belgium)*
- 14:30 Endoscopic management of meningoencephalocele of the olfactory cleft in children**  
*T. Van Den Abbeele (France)*
- 14:45 Endoscopic management of spontaneous CSF leak of the olfactory cleft in adults**  
*C. Rumeau, R. Jankowski (France)*
- 15:00 Endoscopic management of spontaneous CSF leak through a persistent Sternberg's canal**  
*H. Stammberger (Austria)*

**Saturday, December 11 - 2010**

**15:15 – 16:00 ROUND TABLE: CURRENT EXPERIENCE IN OLFACTORY CLEFT INVESTIGATIONS**

Moderators: *B. LANDIS (Switzerland), P. ROMBAUX (Belgium)*

Our experience with olfactory cleft disorders: *P. Eloy (Belgium)*

Empty nose syndrome and olfactory dysfunction: *P. Rombaux (Belgium)*

Ortho-and retranasal olfaction: *B. Landis (Switzerland)*

*Question from the audience*

**16:00-16:30 Coffee break – Partners' exhibition**

## **SURGERY OF THE PARANASAL SINUSES**

**16:30 – 18:30 SURGERY OF THE MAXILLARY PARANASAL SINUS**

Moderators: *T. VAN DEN ABBEELE (France),*

*A. JIMENEZ CHOBILLON (Mexico)*

- 16:30 Recurent acute maxillary sinusitis and middle antrostomy**  
*R. Jankowski (France)*
- 16:45 Chronic maxillary sinusitis and middle antrostomy**  
*H. Stammberger (Austria)*
- 17:00 The rationale for removing fungus balls of the maxillary sinus through middle antrostomy**  
*E. Serrano (France)*
- 17:15 The rationale for removing fungus balls of the maxillary sinus through canina fossa**  
*A. Jimenez-Chobillon (Mexico)*
- 17:30 Radiological assessment of dental sinusitis with the cone beam system**  
*C. Hodez, B. Grignon (France)*
- 17:45 The rationale for endonasal approach to remove benign tumours of the maxillary sinus**  
*P. Eloy (Belgium)*
- 18:00 The rationale for external approach to remove benign tumours of the maxillary sinus**  
*D. Stoll (France)*

**Saturday, December 11 - 2010**

**18:15-18:30** Questions from the audience

**18:30-19:15** Symposium Collin-Storz:

From instrumentarium to new technologies in rhinology  
Specific features and advantages of some instruments in  
endoscopic ethmoid surgery

*R. Jankowski (France)*

Why and how to use Digipointeur in sinus and skull base  
surgery

*B. Lombard (France)*

**19:15** Cocktail on the exhibition



**Sunday, December 12 - 2010**

## **FUNCTIONAL AND AESTHETIC SEPTORHINOPLASTY IN THE LIGHT OF PHYLO-ONTOGENY**

**08:00 – 08:40** **PHYLOGENY AND ONTOGENY OF THE SEPTO-NASAL PYRAMID**  
Moderators: *A. SOUSA VIEIRA (Portugal), F. DISANT (France)*

**08:00** “When bigger is better... on the phylogeny of the nasal pyramid”  
*AJ. Tasman (Switzerland)*

**08:20** **Phylo-ontogenic origin of the nasal septum and pyramid**  
*R. Jankowski (France)*

**08:40 – 10:00** **DYSFUNCTION AND DYSMORPHISM DUE TO ABNORMAL  
GROWTH OF THE SEPTO-NASAL PYRAMID**  
Moderators: *JP. BESSEDE (France), D. WILLATT (UK)*

**08:40** **Natural relationships between nasal septum and pyramid  
deformities**  
*JP. Bessede (France)*

**09:00** **Nasal tip dysmorphism**  
*F. Disant (France)*

**09:20** **Imaging in rhinoplasty (conventional, computer design, CT scan,  
Xenon, radiology)**  
*AJ. Tasman (Switzerland)*

**09:40** **Role of septum deformity, nasal valve and inferior turbinate in  
nasal obstruction**  
*L. de Gabory (France)*

**10:00 – 11:00** **FUNTIONAL REPAIR**  
Moderators: *O. GERBAULT (France), A. SOUSA VIEIRA (Portugal)*

**10:00** **Inferior turbinate management in nasal obstruction**  
*D. Willatt (UK)*

**10:20** **Cottle septoplasty**  
*D. Stoll (France)*

**Sunday, December 12 - 2010**

**10:40 Surgery of the nasal valve**

*F. Disant (France)*

**11:00 – 11:30 Coffee break– Partners' exhibition**

**11:30 – 14:30 MORPHOLOGICAL, FUNCTIONAL AND AESTHETIC REPAIR**

*Moderators: D. STOLL (France), AJ. TASSMAN (Switzerland)*

**11:30 Closed approach in functional and aesthetic septorhinoplasty**

*AJ. Tasman (Switzerland)*

**11:50 Open approach in functional and aesthetic septorhinoplasty**

*A. Sousa Vieira (Portugal)*

**12:10 Functional and aesthetic septorhinoplasty by modelling  
disarticulation**

*R. Jankowski (France)*

**12:30 Nasal tip surgery**

*F. Disant (France)*

**12:50 Alar base reduction**

*F. Disant (France)*

**13:10 Nasal augmentation and camouflage**

*O. Gerbault (France)*

**13:30 Questions from the audience**



## GENERAL INFORMATION

### FACULTY OF MEDICINE OF NANCY VENUE :

Faculty of Medicine of Nancy  
9 avenue de la Forêt de Haye  
54505 VANDOEUVRE-LES-NANCY

### LANGUAGE

All sessions are only in English.  
No translation in any language.

### COMING TO NANCY

To find Nancy in Europe :

	Paris	Dijon	Strasbourg	Luxembourg	Lyon	Bruxelles	Sarrebrück
Nancy	195 miles	130 miles	100 miles	70 miles	250 miles	205 miles	80 miles

Travel discount  

Event: *IESRT 2010*

Event ID: *11122AF*

Valid for travel from *du 05/12/10 au 17/12/10*

Event location: *Nancy, France*

Discounts are applied to a wide range of airfares on all Air France and KLM flights worldwide, if passengers are travelling on the following classes of travel: Espace Affaires [Business] and Economique [Coach]. 10% rebate is applied on published non-restrictive public fares.

A reduction of -5% is granted on restrictive-discounted fares.

Discounts up to -47%\* are offered on domestic flights in Metropolitan France. Contact the dedicated travel agency to access:

- the preferential fares granted for this event,
- make your online reservation,
- issue your electronic ticket.

Keep the document to justify the special fares with you as you may be asked for it at any point of your journey.

### ACCESS :

- By Tramway  
Tramway 1 terminus Brabois Hospital  
20 minutes from city centre
- By car  
10 minutes from city centre  
Free parking

**Frequent flyer / loyalty programs** of Air France and KLM partner airlines are credited with «miles» when Air France or KLM flights are used.

### SNCF :

To benefit from train discounts, please ask for a SNCF discount voucher. This voucher is available upon request by ticking the box on the registration form.

To obtain a discount rate on train, the reservation has to be done in a French train station, in a SNCF agency or in an accredited travel agency. During your journey you must keep your discount voucher as it may be required in case of control.

### Coming by train

The TGV EST -

Eastern France-Europe high speed train

Website : <http://www.tgv.com>

You have the possibility to receive an SNCF rebate voucher (cf Registration Form).

## GENERAL INFORMATION

### Main train lines (TGV)

Paris–Nancy: 90 minutes

Lyons–Nancy: 240 minutes

Strasbourg–Nancy: 75 minutes

Dijon–Nancy: 150 minutes

Luxembourg–Nancy: 90 minutes

### Nancy Railway Station

3, Place Thiers

Phone: +33(0)836 35 35 35

(daily from 7 am to 10 pm)

Website: <http://www.sncf.fr>

The station is located only 5 minutes walk from the city centre and the Place Stanislas.

Open daily from 5.30 am to 10.30 pm

Possible pick up at the railway station with: Lorraine Evasion Aéroports

(personal welcome at the railwail station)

35 bis rue de Malzeville - 54000 Nancy

Phone: +33(0)383 30 97 17

Fax: +33(0)383 30 97 19

Website: <http://www.navettes-aeroports.com>

### Coming by plane

Metz-Nancy Lorraine Regional Airport,  
57420 Goin

Phone: +33(0)387 567 000

Fax: +33(0)387 567 054

Website:

<http://www.metz-nancy-lorraine.aeroport.fr>

Only 28 miles north of Nancy on the A31 motorway.

A frequent shuttle bus runs to and from Nancy (timetables on the Airport website).

You have the possibility to receive an AIR France voucher (cf Registration Form).

### Coming by car

From Paris or Strasbourg: take the A4 motorways.

From Brussels, Luxembourg and Dijon: take the A31 motorway.

### Taxis

Nancy taxis are available 24-hours a day, seven days a week.

Phone: +33(0)383 376 537

Website: <http://www.taxisnancy.com>

### ACCOMMODATION

For your booking accommodation, please contact:

CARLSON WAGONLIT VOYAGES

c/o EUROPA ORGANISATION

Immeuble CENTREDA

1, avenue Didier Daurat

31700 Blagnac - France

E-mail: [cdoumergue@europa-organisation.com](mailto:cdoumergue@europa-organisation.com)

Tel: +33 (0)5 61 16 23 03

Fax: +33 (0) 5 61 40 15 29

Website: [www.iesrt.com](http://www.iesrt.com)

Accommodation

Rooms have been booked in various hotels for the IESRT's attendees.

### COCKTAIL

A cocktail will be served on the exhibition on Saturday, December 11<sup>th</sup> from 19:15.

### CONTACT

For any information, please contact:

#### EUROPA ORGANISATION

5, rue Saint-Pantaléon – BP 61508

31015 TOULOUSE Cedex – France

Phone: +33 (0)5 34 45 26 45

Fax: +33 (0)5 34 45 26 46

E-mail: [insc-iesrt@europa-organisation.com](mailto:insc-iesrt@europa-organisation.com)

Website: <http://www.iesrt.com>

Traitement symptomatique de la rhinocoryza allergique saisonnière (rhume des foins), perannuelle et de l'urticaire

Quand il y a  
de l'**allergène** dans l'air...



## Mizollen® 10 mg mizolastine

L'allergie, il ne peut pas la voir...  
il ne peut pas la sentir!

**MIZOLLEN 10 mg**, comprimé pelliculé à libération modifiée. **COMPOSITION** : Mizolastine 10 mg Excipient dont huile de ricin hydrogénée, q.s.p. un comprimé pelliculé. **FORME PHARMACEUTIQUE** : Comprimé pelliculé à libération modifiée. Comprimé blanc, oblong avec une ligne médiane sur une face et la gravure "MIZ 10" sur l'autre face. **DONNÉES CLINIQUES** : **Indications thérapeutiques** : Traitement symptomatique de la rhinocoryza allergique saisonnière (rhume des foins), de la rhinocoryza allergique perannuelle et de l'urticaire. **Posologie et mode d'administration** : Adultes, y compris les sujets âgés, et enfants de plus de 12 ans. La dose quotidienne recommandée est d'un comprimé à 10 mg, C.T.J. : 0.41 à 0.43. **Contre-indications** : Hypersensibilité à la mizolastine ou à l'un des excipients.

Traitement concomitant par des antibiotiques macrolides ou des antioxydants systémiques de type mizolastine. Traitement concomitant par un médicament connu pour allonger l'intervalle QT, par exemple les antiarythmiques de classe I et II. **Altérations significatives des fonctions hépatiques** : Cardiopathie cliniquement significative ou antécédents de trouble du rythme symptomatique. Patients ayant un allongement connu ou suspecté de l'intervalle QT ou un déséquilibre électrolytique, en particulier une hypokaliémie. Brucyrdie cliniquement significative. **Mises en garde et précautions particulières d'emploi** : La mizolastine a un faible potentiel d'allongement de l'intervalle QT ; il n'a été observé que dans quelques cas. Le degré de l'allongement est modeste et n'a pas été associé avec des troubles du rythme cardiaque. En raison de la présence du lactose, ce médicament est contre-indiqué en cas de galactosémie congénitale, de syndrome de malabsorption du glucose et du galactose ou de déficit en lactase. **Interactions avec d'autres médicaments et autres formes d'interactions** : Association contre-indiquée au kétoconazole ou à l'érythromycine : augmentation modérée de la concentration plasmatique de mizolastine. Association avec prodrugs ou autres inhibiteurs de l'oxydation hépatique (cytochrome P450 3A4) dont cimétidine, cidofovir et nifédipine. **Grossesse et allaitement** : Par mesure de précaution, l'administration de mizolastine doit être évitée pendant la grossesse, particulièrement au cours du premier trimestre. L'administration de la mizolastine n'est pas recommandée chez la femme allaitante. **Effets sur l'aptitude à conduire des véhicules et à utiliser des machines** : La plupart des patients traités par la mizolastine peuvent conduire un véhicule ou effectuer des tâches complexes. **Effets indésirables** : Fréquentes : diarrhée, douleurs abdominales (incluant les dyspepsies), sécheresse buccale, nausées, céphalées, vertiges, somnolence et asthénie souvent transitoires, augmentation de l'appétit accompagnée d'une prise de poids. Peu fréquents : anxiété, dépression, élévation des enzymes hépatiques, hypotension, tachycardie, palpitations, arthralgies et myalgies. Très rares : neutropénie, réactions allergiques, malaise vagal pouvant aller jusqu'à la syncope. Rares cas de variations mineures de la glycémie et du ionogramme ; surveillance périodique chez les patients à risque. Des cas de bronchospasme et d'aggravation d'un asthme ont été rapportés (relation de causalité incertaine en raison de l'incidence élevée de l'asthme dans la population traitée). Troubles digestifs en raison de la présence d'huile de ricin. **PROPRIÉTÉS PHARMACOLOGIQUES** : **Propriétés pharmacodynamiques** : ANTHISTAMINIQUE PAR VOIE SYSTÉMIQUE. La mizolastine possède des propriétés anti-allergiques, et antihistaminiques dues à un blocage spécifique et sélectif des récepteurs périphériques H1 à l'histamine. Chez l'homme, des études de la réaction érythématopapuleuse induite par l'histamine montrent que la mizolastine 10 mg est un antihistaminique rapide, puissant (inhibition de 80 % à 4 heures) et d'action prolongée (24 heures). Aucune tachyphylaxie n'a été observée après traitements prolongés. Les études précliniques et cliniques n'ont révélé aucun effet anticholinergique. **Propriétés pharmacocinétiques** : L'absorption de la mizolastine est rapide après une administration orale. La concentration plasmatique maximale apparaît après un délai médian de 1,5 heure. La biodisponibilité est de 65 % et la cinétique est linéaire. La demi-vie moyenne d'élimination est de 13 heures, avec une liaison de 96,4 % aux protéines plasmatiques. La principale voie métabolique est la glucuronocouplage de la molécule mère. **NUMÉRO D'IDENTIFICATION ADMINISTRATIVE** : 363 977.7 : 15 comprimés sous plaquettes thermoformées (Aluminium/Polyamide-aluminium-PVC). 363 980.8 : 30 comprimés sous plaquettes thermoformées (Aluminium/Polyamide-aluminium-PVC). **CONDITIONS DE PRÉSCRIPTION ET DE DELIVRANCE** : LISTE I. PRIX : 6,43 € (15 comprimés), 12,32 € (30 comprimés). Remboursement Sécurité Sociale à 35 % - Agrie Collectivités. Pour une information complète, consulter le répertoire des spécialités pharmaceutiques sur le site [www.ahaap.fr](http://www.ahaap.fr). **TITULAIRE DE L'AUTORISATION DE MISE SUR LE MARCHÉ** : THERABEL EUROPE Limited - ICA Industrial Estate - Dublin Road - LOUGHREA Co. Galway - Irlande. **EXPLOITANT** : THERABEL, LUCIEN PHARMA - 19 rue Alphonse de Neuville - 75017 Paris - France - Tél. : 01 44 40 57 00. **DATE DE REVISION** : 23/11/2000.

**THERABEL**  
Lucien Pharma